Neurocrine biosciences presents new ingrezza® (valbenazine) data on tardive dyskinesia improvement and stability of psychiatric symptoms at american psychiatric association annual meeting 2022

San diego , may 23, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present data on the use of ingrezza® (valbenazine) capsules for the treatment of tardive dyskinesia (td) at the american psychiatric association (apa) annual meeting being held in person may 21-25 in new orleans and virtually june 7-10. neurocrine biosciences, the leading neuroscience-focused company in the treatment of td, will present findings from a post hoc analysis of two long-term studies of ingrezza evaluating global td improvement and stability of psychiatric symptoms (poster title: poster #p7-088 global improvements and psychiatric stability in adults with tardive dyskinesia: post hoc analyses of two long-term valbenazine studies).
NBIX Ratings Summary
NBIX Quant Ranking